公司概况 - 公司是一家专注于发现和开发针对肝脏相关疾病的创新药物候选品和诊断解决方案的晚期临床生物制药公司[269] - 公司的管道涵盖多个治疗领域，包括原发性胆汁性胆管炎、急性慢性肝功能衰竭、肝性脑病、胆管癌、尿素循环障碍和有机酸血症等[269] 财务状况 - 2023年12月31日，公司营收为28,565千欧元，较2022年12月31日的20,195千欧元增长41.7%[279] - 2023年12月31日，公司研发支出为46,503千欧元，较2022年12月31日的35,818千欧元增长29.8%[281] - 2023年12月31日，公司财务收入为3,680千欧元，较2022年12月31日的8,212千欧元下降55.2%[281] 资金情况 - 公司自成立以来一直通过发行股本和可转换债券、来自BPI France的有条件预付款和补贴、研究税收抵免以及来自Ipsen协议的1200万欧元的前期里程碑获得资金[270] - 公司的经营活动现金流为2021年为99,915千欧元，2022年为-72,638千欧元，2023年为-55,429千欧元，主要受到研发支出和收入的影响[294] - 公司通过现有的流动性、股权发行、债务融资、合作、战略联盟和许可安排等方式来融资运营活动，以支持产品开发和未来商业化努力[297] 董事会和管理团队 - 公司董事会由3至18名成员组成，任期为五年[347] - 公司董事会成员包括来自法国、美国等不同国家的代表[348] - 公司的首席信息官负责引导技术战略、监督技术部署和管理运营[457] 法律合规和治理 - 公司遵循法国公司治理实践，而非纳斯达克上市规则[357] - 公司遵守法国法律要求，而非纳斯达克规定，以获得股东批准发行证券[450] - 公司实施了各种信息安全流程来评估和管理IT系统的安全性[454]

Exhibit 99.1 Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease Paris (France); June 30, 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced positive topline data from the pivotal ELATIVE® Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α,δ PPAR agonist, is being assessed for the treatment of patients wit ...

Exhibit 99.1 GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 18, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 2022 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual ...

| UNITED STATES | | --- | | SECURITIES AND EXCHANGE COMMISSION | | WASHINGTON, D.C. 20549 | | FORM 20-F | | (Mark One) | | o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | OR | | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | x | | For the fiscal year ended December 31, 2022 | | OR | | o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | OR | | o SHELL COMPANY REPORT PURSUA ...

Corporate Presentation April 2022 Disclaimer & Looking Forward Statement IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED BY THIRD-PARTY CONSULTANTS AND OTHER INDUSTRY SOURCES. WHILE GENFIT BELIEVES THAT SUCH INFORMATION IS ACCURATE AND THAT THE SOURCES FROM WHICH IT HAS B ...

Genfit SA (NASDAQ:GNFT) Q4 2021 Earnings Conference Call April 8, 2022 8:00 AM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - Chief Executive Officer Tom Baetz - Chief Financial Officer Dean Hum - Chief Scientific Officer Carol Addy - Chief Medical Officer Conference Call Participants Thomas Smith - SVB Leerink Arsene Guekam - Kepler Cheuvreux Ed Arce - H.C. Wainwright Operator Good day, and welcome to the Genfit's Full-Year 2021 Financial Results and Corporate Upd ...

GENFIT SA (NASDAQ:GNFT) Q2 2020 Results Conference Call September 30, 2020 4:30 PM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - CEO Dean Hum - Chief Scientific Officer and COO Conference Call Participants Thomas Smith - SVB Leerink Derek Archila - Stifel Thomas Yip - H.C. Wainwright Operator Greetings and welcome to the GENFIT Half Year 2020 Financial Report and New Corporate Strategy Conference Call. At this time, all participants are in a listen-only mode. A qu ...

June 19, 2020 2020 CORPORATE PRESENTATION 2020 Disclaimer & Forward Looking Statements IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED BY THIRD-PARTY CONSULTANTS AND OTHER INDUSTRY SOURCES. WHILE GENFIT BELIEVES THAT SUCH INFORMATION IS ACCURATE AND THAT THE SOURCES FROM ...